Mitchell LIU


Mitchell C.C. Liu, MDCM, FRCPC is a Clinical Associate Professor of Radiation Oncology at, BC Cancer Vancouver Center.  Dr. Liu completed his radiation oncology residency at McGill University and a radiation oncology fellowship at Massachusetts General Hospital in Boston. He is currently in the Lung and GI team and has been involved in SABR treatments of lung, liver, spine and oligometastases.  He has been involved in SABR clinical trials including: SABR-COMET, COMET-3, CCTG SC.24, etc


Oligometastatic diseases are essentially early metastases which are limited in number and location. The hypothesis is that in carefully selected patients, aggressive local treatment (such as surgery, RFA or Stereotactic ablative radiotherapy (SBRT/SABR)) could improve their clinical outcome.  The identified prognostic factors tend to be related to: young age, patient fitness, slow-growing disease (i.e., metachronous metastases or a long disease free interval between the original cancer and the metastatic recurrence), low disease burden (i.e., a smaller number of metastases) and effective use of systemic therapies.  SABR-COMET which randomized patients to have SABR vs Standard of Care showed that the SABR arm has better local control and PFS , as well there is a trend of improvement in OS. Updates on this study and other SABR trials will be presented.

Share This Speaker
Speaker Details
  • Location
  • Affiliations of the Speaker
    University of British Columbia, Canada
Radiotherapy for lung cancer

8th November 2020,16:00pm

Events of the Speaker
You might also love these events.
November 7, 2020
The highlights for the 7th HKIOS include application of artificial intelligence in radiotherapy planning and biomarkers discovery, ultra-high dose rate (FLASH) radiotherapy and alternating electric fields (tumour treating fields or TTF). Many oncologists are not familiar with these brand-new modalities, which are being slowly incorporated into our clinical practice. Due to Covid-19 pandemic, we shall conduct our symposium virtually. We thank our local and overseas speakers for their stern support and contribution again.
October 26, 2019
The 6th Hong Kong International Oncology Symposium (6th HKIOS) was conducted in Sheraton Hong Kong Hotel & Towers on 26th and 27th October. The event was joined by renowned speakers with a higher international representation, reflecting our initiatives in fostering international medical collaborations. Some emerging topics such as artificial intelligence, immunotherapy and radiotherapy were discussed in the symposium.